Little progress has been made in treating breast cancer that has already disseminated to bone (5), largely because we lack a comprehensive understanding of molecular mechanisms that make ER+ breast cancer cells more aggressive in the bone marrow niche (6). This evidence concerns the gene ESR1 and breast carcinoma.